New Rewards Coming Soon!¡Se vienen nuevas recompensas!
Our Healthy Rewards Program is getting an update in September! For a sneak peek of all the changes - including new rewards and ways to redeem them - please click here.
¡Nuestro Programa Healthy Rewards tendrá su actualización en septiembre! Para ver un adelanto de todos los cambios, incluyendo nuevas recompensas y formas de canjearlas, haz clic aquí.
Date: December 7, 2021
Attention: Primary Care Providers and Pulmonologists
Subject: Dupixent (dupilumab) Criteria Update
Effective Date: October 20, 2021Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Effective October 20, 2021, Texas Medicaid revised criteria of the Dupixent (dupilumab). Dupixent is FDA-approved as an add-on maintenance treatment for individuals 6 years and older with moderate-to-severe eosinophilic phenotype asthma, or with oral corticosteroid dependent asthma.
How this impacts providers: The previous criteria required individuals to be 12 years and older for diagnosis of moderate to severe asthma. The revised criteria omits that step to expand treatment to individuals 6 years and older.
Next steps for providers: Providers need to use updated prior authorization forms and providers should share this update with their staff as well.
Resources:
